Skip to main content

Table 1 Characteristics of the study population

From: Both intermuscular fat and LVEF decline promote heart failure symptoms in cancer survivors

  Overall
(N = 62)
Gender
 Female 41 (66.1%)
 Male 20 (32.3%)
 Missing 1 (1.6%)
Race
 White 48 (77.4%)
 Black 12 (19.4%)
 Other 1 (1.6%)
 Missing 1 (1.6%)
Cancer Type
 Breast 23 (37.1%)
 Lymphoma 33 (53.2%)
 Sarcoma 6 (9.7%)
Coronary Artery Disease
 No 58 (93.5%)
 Yes 4 (6.5%)
Smoking History
 No 42 (67.7%)
 Yes 20 (32.3%)
Diabetes
 No 52 (83.9%)
 Yes 10 (16.1%)
Hypertension
 No 40 (64.5%)
 Yes 22 (35.5%)
Anthracycline
 No 20 (32.3%)
 Yes 42 (67.7%)
Diuretic
 No 50 (80.6%)
 Yes 12 (19.4%)
Beta Blocker
 No 58 (93.5%)
 Yes 4 (6.5%)
ACE Inhibitor
 No 53 (85.5%)
 Yes 9 (14.5%)
Angiotensin Receptor Blocker
 No 58 (93.5%)
 Yes 4 (6.5%)
Calcium Channel Blocker
 No 57 (91.9%)
 Yes 5 (8.1%)
Lipid Lowering Drugs
 No 42 (67.7%)
 Yes 20 (32.3%)
Baseline IMF, cm2
 Mean (SD) 9.13 (4.08)
Baseline BMI, kg/m2
 Mean (SD) 30.0 (5.76)
Change in EF from Baseline, %
 Mean (SD) −5.12 (8.25)
Baseline Systolic BP, mmHg
 Mean (SD) 119 (17.5)
Baseline Diastolic BP, mmHg
 Mean (SD) 69.8 (13.5)